Swiss Life Sciences Stock News

SoftwareOne Holding (SWX:SWON) has been appointed one of the first global authorized Google Cloud distributors, with new distribution rights across 10 launch markets and extended support for partners using Google Cloud services. See our latest analysis for SoftwareOne Holding. The new Google Cloud distribution role arrives after a tough stretch for the share price, with a 30 day share price return of a 13.28% decline and a 90 day share price return of a 23.32% decline, even as the 1 year...

Idorsia (SWX:IDIA) reports materially higher sales for its insomnia drug Quvivic, reflecting stronger commercial traction. The company secures public reimbursement for Quvivic across additional key healthcare markets. Idorsia expands Quvivic access into new geographies while pursuing fresh partnerships and distribution agreements. Progress continues in its pediatric insomnia study and across several pipeline candidates in different therapeutic areas. Idorsia, a biopharmaceutical company...

Why Sensirion’s upcoming earnings are on investors’ radar Sensirion Holding (SWX:SENS) is drawing attention ahead of its 10 March 2026 earnings release, as investors watch how demand for sensors in AI and IoT devices shows up in the latest numbers. The focus is on how the company’s cash position and R&D spending support its role as a potential growth play in AI related hardware, and whether new guidance shifts sentiment around the stock. See our latest analysis for Sensirion Holding. Despite...

Alcon (SWX:ALC) is in the spotlight after reporting fourth quarter 2025 earnings, with higher sales and revenue alongside lower net income, while also proposing a dividend and drawing attention for its intraocular lens business. See our latest analysis for Alcon. Alcon’s share price is now at CHF65.24, with a 1 month share price return of 5.29% and a year to date share price return of 2.68%. The 1 year total shareholder return of 21.63% decline contrasts with modest 3 year and 5 year total...

In February 2026, Swiss Re reported full-year 2025 net income of US$4,740 million, sharply higher than the prior year, and announced a share repurchase program of up to US$1.50 billion authorized by its Board, running through December 31, 2026 subject to legal and regulatory approvals. Together with the appointment of Anne Lohbeck as chief risk officer for PC Re, these moves highlight Swiss Re's focus on capital return and risk oversight alongside improved profitability. We’ll now examine...

The EMA’s Committee for Medicinal Products for Human Use has issued a positive opinion for Novartis’s remibrutinib for chronic spontaneous urticaria. The recommendation supports marketing authorization in the EU for a highly selective oral BTK inhibitor targeting patients with unmet treatment needs. Novartis (SWX:NOVN) is a large global pharmaceutical group with a focus on immunology and other specialty therapies, so progress on remibrutinib fits squarely within its core franchise. For...

Kuehne + Nagel International (SWX:KNIN) FY 2025 Results: Margins In Focus After Softer Q4 Kuehne + Nagel International (SWX:KNIN) has wrapped up FY 2025 with fourth quarter revenue of CHF5.95b and basic EPS of CHF1.32, alongside net income of CHF157m. These results frame how investors may assess the full year at a share price of CHF180.45. The company’s quarterly revenue moved from CHF6.76b in Q4 2024 to CHF6.33b in Q1 2025 and then to CHF5.95b in Q4 2025, while basic EPS shifted from CHF2.50...

Roche Holding (SWX:ROG) is back in focus after Genentech reported that fenebrutinib met the primary endpoint in the pivotal Phase III FENhance 1 trial in relapsing multiple sclerosis, with statistically significant efficacy versus teriflunomide. See our latest analysis for Roche Holding. The fenebrutinib update lands after a series of drug pipeline milestones and conference appearances. It comes with a 90 day share price return of 15.7% and a 1 year total shareholder return of 22.3%, which...

Latest FY 2025 Results Snapshot SIG Group (SWX:SIGN) has posted a mixed FY 2025 picture, with second half revenue of €1.7b and a basic EPS loss of €0.47, while trailing twelve month revenue sits at €3.2b alongside a basic EPS loss of €0.23. The company has seen revenue move from €1.8b and basic EPS of €0.29 in the second half of 2024 to €1.7b and a basic EPS loss of €0.47 in the second half of 2025, highlighting pressure on earnings even as the business scale remains large. For investors, the...

Bucher Industries (SWX:BUCN) has posted fresh FY 2025 numbers, reporting first half revenue of CHF 1,537.3 million and basic EPS of CHF 13.98. This follows revenue of CHF 1,724 million and EPS of CHF 14.07 in the first half of 2024, and CHF 1,431.5 million with EPS of CHF 8.09 in the second half of 2024. The company has also reported trailing twelve month revenue between CHF 2,914.3 million and CHF 3,155.5 million, with TTM EPS ranging from CHF 22.06 to CHF 23.22, setting the scene for...

Temenos (SWX:TEMN) has drawn fresh attention after releasing its 2025 full year results together with an annual dividend announcement of CHF 1.40 per share, a combination many investors watch closely. See our latest analysis for Temenos. Temenos shares are trading at CHF 72.60, and the latest full year earnings together with the CHF 1.40 dividend announcement appear to have supported a 4.91% 1 month share price return, even though the year to date share price return is a decline of 10.92% and...

Why VAT Group’s latest earnings matter for shareholders VAT Group (SWX:VACN) reported record 2025 sales, EBITDA, and free cash flow, yet paired those figures with a cautious Q1 2026 revenue outlook that fell short of analyst expectations. That mix of strong historical results and softer near term guidance, along with an upbeat longer term view from management, has put the stock under closer scrutiny as investors reassess how much optimism is already reflected in the current share price. See...

ALSO Holding AG has announced a €120 million share buyback program, equivalent to roughly 5% of its market value, with repurchased shares earmarked for potential acquisitions, liquidity support, and long-term performance-based incentives. This buyback framework is unusual in that it explicitly links repurchased shares to future deal-making capacity as well as employee incentive structures, highlighting how capital allocation and corporate development priorities intersect at the...

Amrize (SWX:AMRZ) has introduced its new EVERtect™ high-performance concrete range for customers in North America. The portfolio includes multiple specialized mixes tailored for different construction uses across the U.S. and Canada. The launch expands Amrize’s presence in high-spec concrete solutions for both structural and low-carbon applications. For you as an investor, this move highlights how Amrize is positioning its core materials business around more differentiated, higher-spec...

Sika (SWX:SIKA) has drawn fresh attention after signing a commercial partnership with Canada based Giatec Scientific to integrate AI driven concrete technology into its products, alongside ongoing global plant expansions and digital investments. See our latest analysis for Sika. Despite the fresh Giatec partnership and recent announcements on earnings, guidance, new plants, and dividends, Sika’s recent momentum has been soft, with a 30 day share price return of 2.19% against a year to date...

If you are wondering whether ABB's current share price still makes sense after a strong run, this article breaks down what you are really paying for the business today. ABB shares last closed at CHF 67.20, with returns of 46.1% over 1 year and 181.5% over 5 years. The shorter term picture is mixed, with a 4.8% decline over 7 days but a 9.7% gain year to date. Recent headlines have focused on ABB's ongoing position as a major player in electrification and automation, as well as its exposure...

Alcon reports that more than 175 million of its intraocular lenses have been implanted worldwide. The milestone highlights broad adoption of the company’s presbyopia-correcting IOLs across global eye care practices. Alcon plans further intraocular lens launches, subject to regulatory approvals. For investors following Alcon (SWX:ALC), this update comes with the shares trading at CHF63.96 and a value score of 4. The stock shows a 22.3% decline over the past year, while 3-year and 5-year...

Kuehne + Nagel International (SWX:KNIN) reported a substantial decline in recurring operating earnings. Full year results show lower recurring earnings before interest and tax compared with the prior year. Net income for the same period also moved lower, pointing to pressure on overall profitability. The figures highlight ongoing challenges across the transport and logistics sector. Kuehne + Nagel is a major global player in sea, air, and contract logistics, so its results often provide a...

Why Emmi’s latest earnings matter for shareholders Emmi (SWX:EMMN) has just reported its full year 2025 results, with revenue of CHF 4,745.69 million and net income of CHF 227.06 million, putting fresh fundamentals in focus for anyone tracking the stock. See our latest analysis for Emmi. Emmi’s 12.0% 90 day share price return and 13.57% year to date share price return suggest momentum has picked up ahead of these results, even though the 1 year total shareholder return is slightly...

UBS Group (SWX:UBSG) has nominated Agustín Carstens and Luca Maestri to join its Board of Directors. The nominations come alongside the planned retirement of several long-serving board members. The board changes are tied to UBS’s ongoing integration of Credit Suisse and evolving regulatory expectations. UBS Group, a global wealth manager and investment bank, is in the middle of absorbing Credit Suisse while operating under tighter regulatory scrutiny. Bringing in leaders with regulatory,...

Forbo Holding (SWX:FORN) has released its FY 2025 first half results with revenue of CHF 546.9 million and basic EPS of CHF 23.70, while trailing 12 month figures show revenue of CHF 1.10 billion and EPS of CHF 56.78. Over the last few reporting halves, revenue has moved from CHF 570.3 million and EPS of CHF 34.36 in 1H 2024 to CHF 551.7 million and EPS of CHF 33.07 in 2H 2024, before landing at the latest 1H 2025 levels. The trailing 12 month net profit margin now sits at 7.3% versus 8.3% a...

On 24 February 2026, Iconovo AB announced it had signed a Letter of Intent with Lonza Group to pursue a long-term collaboration around spray dried formulation capabilities for inhalable biologics, building on their existing work on an obesity project. This potential alliance links Lonza’s CDMO scale with Iconovo’s five-platform inhaler technology targeting biologics and high-value respiratory franchises with global turnover of about US$9.00 billion. We’ll now examine how this focus on spray...

Avolta AG recently completed the cancellation of about 4.9 million treasury shares, reducing its registered share capital to CHF 708,241,695 across 141,648,339 shares, while continuing to expand its food and beverage footprint at key airports in Italy and Canada. This combination of a tighter share base and integrated travel retail and dining growth highlights Avolta’s focus on capital efficiency alongside strengthening its airport partner relationships. Next, we’ll examine how Avolta’s...

ARYZTA (SWX:ARYN) has kicked off FY 2025 with first half revenue of €1.09b and basic EPS of €1.84, while trailing twelve month figures sit at €2.22b of revenue and EPS of €4.26, giving investors a clear view of the current earnings run rate. The company has seen revenue move from €1.06b and EPS of €1.65 in H1 FY 2024 to €1.14b and EPS of €2.40 in H2 FY 2024, with trailing twelve month net income reaching €112.3m. With a trailing net margin of 5.1% against 4.6% a year earlier, the latest...